loading
전일 마감가:
$4.45
열려 있는:
$4.54
하루 거래량:
1.95M
Relative Volume:
0.63
시가총액:
$441.69M
수익:
$20.65M
순이익/손실:
$-192.65M
주가수익비율:
-1.9093
EPS:
-2.59
순현금흐름:
$-134.39M
1주 성능:
+13.36%
1개월 성능:
-4.77%
6개월 성능:
-30.97%
1년 성능:
-4.77%
1일 변동 폭
Value
$4.50
$5.10
1주일 범위
Value
$3.89
$5.10
52주 변동 폭
Value
$2.8647
$9.305

Verve Therapeutics Inc Stock (VERV) Company Profile

Name
명칭
Verve Therapeutics Inc
Name
전화
(978) 501-3026
Name
주소
201 BROOKLINE AVENUE, BOSTON
Name
직원
274
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
VERV's Discussions on Twitter

VERV을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
VERV
Verve Therapeutics Inc
4.955 382.42M 20.65M -192.65M -134.39M -2.59
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.90 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.19 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.39 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.55 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
501.35 65.13B 14.09B 4.50B 2.96B 39.28

Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-15 업그레이드 Cantor Fitzgerald Neutral → Overweight
2024-04-08 개시 H.C. Wainwright Buy
2023-04-13 개시 Canaccord Genuity Buy
2023-02-01 개시 Cantor Fitzgerald Neutral
2022-12-15 개시 Goldman Sell
2022-10-06 개시 Credit Suisse Neutral
2022-08-25 업그레이드 Stifel Hold → Buy
2022-06-17 개시 BMO Capital Markets Outperform
2022-02-18 개시 RBC Capital Mkts Outperform
2021-09-24 개시 Stifel Hold
2021-07-12 개시 Guggenheim Buy
2021-07-12 개시 JP Morgan Neutral
2021-07-12 개시 Jefferies Buy
2021-07-12 개시 William Blair Outperform
모두보기

Verve Therapeutics Inc 주식(VERV)의 최신 뉴스

pulisher
May 29, 2025

Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationVERV - ACCESS Newswire

May 29, 2025
pulisher
May 28, 2025

Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Verve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.

May 28, 2025
pulisher
May 28, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st

May 28, 2025
pulisher
May 22, 2025

Transcript : Verve Therapeutics, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 03 - marketscreener.com

May 22, 2025
pulisher
May 20, 2025

Verve Therapeutics Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st

May 20, 2025
pulisher
May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025
pulisher
May 19, 2025

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts - simplywall.st

May 19, 2025
pulisher
May 19, 2025

Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher - Yahoo Finance

May 19, 2025
pulisher
May 18, 2025

Price T Rowe Associates Inc. MD Lowers Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

May 18, 2025
pulisher
May 17, 2025

Brokerages Set Verve Therapeutics, Inc. (NASDAQ:VERV) PT at $25.75 - Defense World

May 17, 2025
pulisher
May 15, 2025

Dimensional Fund Advisors LP Raises Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

May 15, 2025
pulisher
May 15, 2025

Verve Therapeutics: Q1 Earnings Snapshot - CT Insider

May 15, 2025
pulisher
May 15, 2025

Verve Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 15, 2025
pulisher
May 14, 2025

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Verve Therapeutics (VERV) Beats Q1 EPS Estimates, Reports Signif - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Verve Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Verve Therapeutics (VERV) Exceeds Revenue Estimates and Advances Clinical Trials | VERV Stock News - GuruFocus

May 14, 2025
pulisher
May 12, 2025

Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Wednesday - Defense World

May 12, 2025
pulisher
May 11, 2025

Stifel Financial Corp Purchases 9,736 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

May 11, 2025
pulisher
May 11, 2025

Tower Research Capital LLC TRC Lowers Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

May 11, 2025
pulisher
May 10, 2025

1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street - AOL.com

May 10, 2025
pulisher
May 08, 2025

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

(VERV) Investment Analysis - news.stocktradersdaily.com

May 08, 2025
pulisher
May 08, 2025

Wells Fargo & Company MN Boosts Stake in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

May 08, 2025
pulisher
May 07, 2025

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga

May 07, 2025
pulisher
May 06, 2025

Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com

May 06, 2025
pulisher
May 05, 2025

Invesco Ltd. Buys 3,080 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

May 05, 2025
pulisher
May 03, 2025

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

May 03, 2025
pulisher
May 02, 2025

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 02, 2025
pulisher
Apr 29, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 29, 2025
pulisher
Apr 26, 2025

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire

Apr 26, 2025

Verve Therapeutics Inc (VERV) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Verve Therapeutics Inc 주식 (VERV) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Nickerson Joan
Chief Administrative Officer
Apr 02 '25
Sale
4.15
2,777
11,525
17,420
Ashe Andrew D.
See Remarks
Apr 02 '25
Sale
4.15
2,681
11,126
348,828
Politi Jason
Chief Technical Ops. Off.
Apr 02 '25
Sale
4.15
3,235
13,425
14,226
Dorval Allison
Chief Financial Officer
Apr 02 '25
Sale
4.15
3,350
13,903
13,280
Lister Troy
Chief Scientific Officer
Apr 02 '25
Sale
4.15
2,189
9,084
6,952
Dorval Allison
Chief Financial Officer
Dec 02 '24
Sale
5.64
555
3,130
5,380
Kathiresan Sekar
Chief Executive Officer
Jun 28 '24
Option Exercise
2.87
30,000
86,100
351,128
$1.0846
price down icon 1.76%
$29.97
price down icon 0.70%
$577.79
price up icon 0.89%
$306.27
price up icon 0.67%
$4.47
price down icon 2.22%
$489.50
price down icon 0.11%
자본화:     |  볼륨(24시간):